For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 1.2 million shares were traded.
Ratios:
For a better understanding of RGNX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.05 and its Current Ratio is at 3.05. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 30 ’24 when VITTAL VASISTA bought 20,041 shares for $7.41 per share.
KARABELAS ARGERIS N sold 10,000 shares of RGNX for $101,052 on Oct 01 ’24. The Director now owns 11,286 shares after completing the transaction at $10.11 per share. On Sep 03 ’24, another insider, KARABELAS ARGERIS N, who serves as the Director of the company, sold 10,000 shares for $11.56 each. As a result, the insider received 115,588 and left with 11,286 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.48 while its Price-to-Book (P/B) ratio in mrq is 0.97.
Stock Price History:
Over the past 52 weeks, RGNX has reached a high of $28.80, while it has fallen to a 52-week low of $5.91. The 50-Day Moving Average of the stock is -21.09%, while the 200-Day Moving Average is calculated to be -44.05%.
Shares Statistics:
A total of 49.53M shares are outstanding, with a floating share count of 44.72M. Insiders hold about 9.75% of the company’s shares, while institutions hold 87.33% stake in the company.
Earnings Estimates
A comprehensive evaluation of Regenxbio Inc (RGNX) is underway, with the input of 7.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.44, with high estimates of $1.07 and low estimates of -$1.35.
Analysts are recommending an EPS of between -$4.03 and -$5.47 for the fiscal current year, implying an average EPS of -$4.76. EPS for the following year is -$0.43, with 8.0 analysts recommending between $2.63 and -$2.91.
Revenue Estimates
9 analysts predict $23.7M in revenue for the current quarter. It ranges from a high estimate of $31M to a low estimate of $15M. As of the current estimate, Regenxbio Inc’s year-ago sales were $22.21MFor the next quarter, 9 analysts are estimating revenue of $20.51M. There is a high estimate of $25.72M for the next quarter, whereas the lowest estimate is $15M.
A total of 11 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $94.51M, while the lowest revenue estimate was $77.11M, resulting in an average revenue estimate of $87.11M. In the same quarter a year ago, actual revenue was $90.24MBased on 11 analysts’ estimates, the company’s revenue will be $314.86M in the next fiscal year. The high estimate is $495.52M and the low estimate is $203M.
